For example, the immunogenicity of anti-tumor necrosis factor (TNF) α antibodies used to treat rheumatoid arthritis, and of biotherapeutics prescribed to alleviate symptoms of inflammatory bowel disease (IBD), is a significant problem, compounded by the inflammatory milieu of the clinical disorders requiring treatment [10,11,12]. This evidence concerns the gene TNF and inflammatory bowel disease.